BPC-157

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide originally derived from a protein fragment found in human gastric juice. The preclinical research base spans tendon and ligament repair, gut and intestinal healing, wound healing, cardiovascular and central nervous system effects, and a range of musculoskeletal applications - largely studied in rat and mouse models, with smaller cell-culture and biochemistry literature. The human clinical literature is much smaller: only a handful of small published clinical studies exist, and BPC-157 is not a component of any FDA-approved drug. The regulatory status is a meaningful caveat for any consumer-level consideration of the compound.

The outcome dimensions covered most heavily in the preclinical literature are tendon and ligament healing in rodent injury models, gastrointestinal tract repair in animal models of induced injury, wound healing kinetics, and a wide range of organ-protective effects observed in various rodent models. The much smaller human literature has examined a limited subset of these applications, primarily in small pilot studies and one trial reported only as a meeting abstract; the one systematic review to date found 35 preclinical studies and a single clinical study.

The defining feature of the BPC-157 literature is the gap between preclinical and clinical evidence. Most consumer marketing claims are extrapolated from rat studies, and the assumption that effects translate to humans at supplemental doses has not been verified in adequately-powered clinical trials. The compound is sold online as capsules, sprays and injectable vials, including by research-use-only vendors and some pharmacies; product quality, purity, and dose accuracy can vary substantially across sources. Self-administered injection (the most-common route discussed in consumer communities) introduces additional practical considerations beyond standard oral supplementation.

Human safety data for BPC-157 is genuinely limited. The five published clinical studies to date reported no serious adverse events, but they were small and short with limited safety monitoring, and the FDA holds a few adverse-event reports it could not attribute. No tolerable upper limit has been established because the foundational data to set one is lacking. Drug interactions are not characterized in human research. BPC-157 is named on the 2026 World Anti-Doping Agency Prohibited List as a non-approved substance, prohibited at all times. Acute injection-related risks (infection, abscess formation, injection-site reactions) are additional considerations beyond the substance itself, given that self-administered injection is a common consumer route. FDA reviewers have also flagged a possible immune reaction to injected BPC-157 (immunogenicity) as an unstudied risk. The FDA listed BPC-157 in 2023 among bulk substances that may present significant safety risks in compounding. In July 2026 an FDA advisory committee voted to recommend allowing pharmacies to compound it, against the position of FDA reviewers, and advisory votes do not bind the agency. People considering BPC-157 should be aware that they are using a substance without comprehensive human safety characterization and without regulatory approval as a drug; clinician consultation is strongly recommended.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.